Medimmune Limited

Other

Godfrey Rainey

Changshou Gao

Cuihua Gao

Srinath Kasturirangan

Melissa Marie Damschroder

Nicole Kallewaard-LeLay

Qing Zhu

Nazzareno Dimasi

Ryan Fleming

Binyam Bezabeh

Ralph Raymond Minter

Partha S Chowdhury

Charles K Stover

Bret Sellman

Scott A Hammond

Claire Louise Dobson

Ronald Herbst

Reena Varkey

Darren Schofield

Sandrine Guillard

Stacey Drabic

Steven Rust

Antonio Digiandomenico

Michelle Morrow

Yariv Mazor

Paul Warrener

Mladen Tomich

Brian Lobo

Michael Oberst

Prakash Manikwar

Li Peng

Vignesh Venkatraman

Simon Dovedi

Jonathan Seaman

Gianluca Carlesso

Kristen Pollizzi

John H Li

Andy Q Yuan

Steven Roy Coats

Dorin Toader

Fengjiang Wang

Lakshmaiah Gingipalli

Ralph Minter

Andy Qingan Yuan

Partha Chowdhury

Melissa Damschroder

Rust Steven

Charles Stover

This disclosure relates to combination therapies comprising anti-Psl and PcrV binding molecules and related compositions, for use in prevention and treatment ofinfection.

Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

Binding molecules, including bispecific antibodies that include at least two anti-influenza binding domains are disclosed, including binding molecules having a first binding domain that specifically binds influenza A virus and a second binding domain that specifically binds influenza B virus.

Neutralizing anti-influenza binding molecules and uses thereof

This disclosure relates to polynucleotides encoding antibodies or antigen binding fragments thereof that bind toPcrV as well as vectors and host cells comprising the same.

Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv

This disclosure provides conjugate compounds comprising antibodies and fragments thereof engineered with one or more reactive cysteine residues and more specifically to conjugate compounds with therapeutic or diagnostic applications. The conjugate compounds comprise cysteine-engineered antibodies or fragments thereof conjugated, for example, with chemotherapeutic drugs, toxins, and detection labels such as radionuclides or fluorophores. The disclosure also provides methods of using the disclosed conjugate compounds for in vitro, in situ, ex vivo, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

Conjugated compounds comprising cysteine-engineered antibodies

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Bispecific HER2 antibodies

Growing community of inventors

Gaithersburg, MD, United States of America

Godfrey Rainey